We report the case of 52-year-old heart transplant recipient\ud positive for Epstein-Barr virus (EBV) and CD3 polymorphic\ud post-transplant lymphoproliferative disorder (PTLD). At age\ud 39 years, the patient underwent heterotopic heart transplantation\ud for end-stage ischemic dilated cardiomyopathy in a setting\ud of irreversible pulmonary hypertension. He was asymptomatic\ud for 13 years after transplantation. During the intervening\ud period, he sustained an episode of rejection without\ud apparent sequelae. Immunosuppression consisted of cyclosporine,\ud azathioprine, and corticosteroids
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.